Drug Discovery Platform Peptris Raises Rs 70 Cr in Series A Round

Why It Matters

The funding validates AI‑driven drug discovery as a scalable solution to high R&D costs, offering pharma partners faster, lower‑risk access to novel therapeutics. It also positions Peptris to expand its pipeline and influence treatment options in underserved therapeutic areas.

Key Takeaways

• Raised Rs 70 cr ($7.7 m) Series A.
• AI platform generates novel molecules, predicts development parameters.
• Funds to push pipelines to clinical readiness within 24 months.
• Targets rare diseases, oncology, inflammation, women’s health.
• B2B model licenses assets to pharma, biotech partners.

Pulse Analysis

Artificial intelligence is reshaping early‑stage drug discovery by automating molecule design and forecasting key pharmacokinetic attributes. Traditional pre‑clinical programs suffer from high attrition, long timelines, and escalating costs, prompting investors to back platforms that can de‑risk candidates before costly animal studies. Peptris leverages generative models to propose novel chemical entities while simultaneously predicting solubility, toxicity, and manufacturability, thereby shortening the hypothesis‑testing cycle and conserving capital.

The Rs 70 crore Series A injection arrives at a moment when venture capital is gravitating toward biotech ventures that embed data science at their core. Co‑lead investors IAN Alpha Fund and Speciale Invest see Peptris’ dual capability—creating new molecules and rescuing shelved drugs—as a differentiator that can generate licensable assets quickly. The funding earmarked for expanding biology, chemistry, data‑science and AI teams will enable the startup to launch multiple NCE programs and accelerate existing repurposing projects toward IND filings within two years, aligning with industry pressure to deliver therapies faster.

For pharmaceutical and biotech partners, Peptris offers a B2B model that reduces the upfront risk of internal discovery programs. By licensing AI‑derived candidates or co‑developing them, partners can tap into innovative pipelines without bearing the full cost of early research. Focusing on rare diseases, oncology, inflammation, and women’s health—areas with high unmet need—positions Peptris to address market gaps while delivering value to patients and healthcare systems. As AI continues to mature, platforms like Peptris are likely to become integral components of the drug development ecosystem, driving efficiency and expanding therapeutic options.